ADAG
Adagene Inc.
There isn't enough reported data to score ADAG yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ADAG Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ADAG's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADAG PE Valuation
ADAG has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ADAG Forward outlook
There aren't enough analyst estimates for ADAG to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ADAG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.30 | +$0.46 |
| Q2 2025 | -$0.51 | +$0.39 |
| Q4 2024 | -$0.76 | -$0.22 |
| Q2 2024 | -$0.90 | +$0.16 |
| Q1 2024 | -$0.72 | +$1.64 |
| Q4 2023 | -$0.54 | +$2.45 |
| Q3 2023 | -$0.80 | +$2.74 |
| Q2 2023 | -$1.06 | +$2.52 |
LLY has the stronger earnings trend. Trailing diluted EPS is down 142% for ADAG versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
ADAG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $407.9K | -85% |
| Q3 2023 | $407.9K | -85% |
| Q2 2023 | $8.6M | +120% |
| Q1 2023 | $8.6M | +341% |
| Q4 2022 | $2.7M | -69% |
| Q3 2022 | $2.7M | -39% |
| Q2 2022 | $3.9M | +189% |
| Q1 2022 | $2M | +189% |
ADAG has the stronger quarterly revenue trend. Revenue is up 298% for ADAG versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1024% | N/A |
| Q4 2023 | -2289% | -1621 points |
| Q3 2023 | -2289% | -1621 points |
| Q2 2023 | -29% | +1196 points |
| Q1 2023 | -29% | +1196 points |
| Q4 2022 | -668% | -272 points |
| Q3 2022 | -668% | -272 points |
| Q2 2022 | -1225% | +1535 points |
ADAG's operating margin was −1024% last quarter, down 995 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ADAG on profitability, with a higher operating margin.
ADAG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.9M | -$3.8M |
| Q4 2025 | -$4.5M | +$11.8M |
| Q2 2025 | -$11.1M | -$4.4M |
| Q4 2024 | -$16.3M | -$1.3M |
| Q2 2024 | -$6.7M | +$36K |
| Q1 2024 | -$6.7M | +$36K |
| Q4 2023 | -$15.1M | -196% |
| Q3 2023 | $0 | -100% |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with ADAG at down 287%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ADAG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -23% | -13.7M shares |
| 1 year | +28% | +10M shares |
| 3 years | +30% | +10.4M shares |
| 5 years | +65% | +17.8M shares |
| Available history | +367% | +35.6M shares |
ADAG has 45M diluted shares, up 28% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ADAG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ADAG Net Leverage
ADAG's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ADAG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 9.4 | Oversold |
ADAG's weekly RSI is 36 (neutral) and its Stochastic is 9 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ADAG PE vs Healthcare Sector
ADAG has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ADAG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.44 | 18% below |
| 20 week MA | $3.21 | 38% below |
| 50 week MA | $3.15 | 37% below |
| 100 week MA | $2.51 | 20% below |
| 200 week MA | $2.30 | 13% below |
ADAG is in a downtrend: it's below all five of its weekly moving averages, and 13% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ADAG on trend strength, trading above more of its moving averages.
ADAG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $27.7 | $7.50 | -73% |
| 2022 | $7.50 | $1.26 | -83% |
| 2023 | $1.26 | $1.93 | +53% |
| 2024 | $1.93 | $1.96 | +1.6% |
| 2025 | $1.96 | $1.78 | -9.2% |
| 2026 YTD | $1.78 | $2.00 | +12% |
ADAG has finished lower in three of the last five years. It's up 12% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ADAG on returns for 2026, with the stronger performance.